70 results on '"Brück O"'
Search Results
2. Topic: AS07-Singular Entities/Subtypes/AS07e-Chronic myelomonocytic leukemia and overlap syndromes (MDS/MPN): UNDERSTANDING CMML BIOLOGY BY INTEGRATIVE ANALYSIS OF EXOME SEQUENCING, RNA SEQUENCING, AND METHYLOME IN A LARGE PATIENT COHORT
- Author
-
Kynning, M. Kjellander, primary, Nannya, Y., additional, Todisco, G., additional, Yoshizato, T., additional, Tesi, B., additional, Mortera-Blanco, T., additional, Björklund, A.-C., additional, Brück, O., additional, Ohyashiki, K., additional, Ishikawa, T., additional, Ochi, Y., additional, Haferlach, T., additional, Mustjoki, S., additional, Hellstrom-Lindberg, E., additional, Ogawa, S., additional, and Ungerstedt, J., additional
- Published
- 2023
- Full Text
- View/download PDF
3. P121 - Topic: AS07-Singular Entities/Subtypes/AS07e-Chronic myelomonocytic leukemia and overlap syndromes (MDS/MPN): UNDERSTANDING CMML BIOLOGY BY INTEGRATIVE ANALYSIS OF EXOME SEQUENCING, RNA SEQUENCING, AND METHYLOME IN A LARGE PATIENT COHORT
- Author
-
Kynning, M. Kjellander, Nannya, Y., Todisco, G., Yoshizato, T., Tesi, B., Mortera-Blanco, T., Björklund, A.-C., Brück, O., Ohyashiki, K., Ishikawa, T., Ochi, Y., Haferlach, T., Mustjoki, S., Hellstrom-Lindberg, E., Ogawa, S., and Ungerstedt, J.
- Published
- 2023
- Full Text
- View/download PDF
4. POSC128 Healthcare Resource Utilization in Adults Diagnosed with Acute Myeloid Leukemia (AML) in Helsinki and Uusimaa Hospital District
- Author
-
Immonen, J, primary, Hemmilä, P, additional, Kurkela, H, additional, Leussu, M, additional, Toppila, I, additional, Porkka, K, additional, and Brück, O, additional
- Published
- 2022
- Full Text
- View/download PDF
5. CLINICAL SIGNIFICANCE OF T-CELL EXHAUSTION IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
- Author
-
Leppä, S., primary, Autio, M., additional, Brück, O., additional, Mustjoki, S., additional, Jørgensen, J., additional, Karjalainen-Lindsberg, M., additional, Beiske, K., additional, Holte, H., additional, Pellinen, T., additional, and Leivonen, S., additional
- Published
- 2019
- Full Text
- View/download PDF
6. Anti-PD1 therapy increases peripheral blood NKT cells and chemokines in metastatic melanoma patients
- Author
-
Hakanen, H., primary, Hernberg, M., additional, Mäkelä, S., additional, Yadav, B., additional, Brück, O., additional, Juteau, S., additional, Kohtamäki, L., additional, Ilander, M., additional, Mustjoki, S., additional, and Kreutzman, A., additional
- Published
- 2018
- Full Text
- View/download PDF
7. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
- Author
-
Ilander, M, Olsson-Strömberg, U, Schlums, H, Guilhot, J, Brück, O, Lähteenmäki, H, Kasanen, T, Koskenvesa, P, Söderlund, S, Höglund, M, Markevärn, B, Själander, Anders, Lotfi, K, Dreimane, A, Lübking, A, Holm, E, Björeman, M, Lehmann, S, Stenke, L, Ohm, L, Gedde-Dahl, T, Majeed, W, Ehrencrona, H, Koskela, S, Saussele, S, Mahon, F-X, Porkka, K, Hjorth-Hansen, H, Bryceson, Y T, Richter, J, Mustjoki, S, Ilander, M, Olsson-Strömberg, U, Schlums, H, Guilhot, J, Brück, O, Lähteenmäki, H, Kasanen, T, Koskenvesa, P, Söderlund, S, Höglund, M, Markevärn, B, Själander, Anders, Lotfi, K, Dreimane, A, Lübking, A, Holm, E, Björeman, M, Lehmann, S, Stenke, L, Ohm, L, Gedde-Dahl, T, Majeed, W, Ehrencrona, H, Koskela, S, Saussele, S, Mahon, F-X, Porkka, K, Hjorth-Hansen, H, Bryceson, Y T, Richter, J, and Mustjoki, S
- Abstract
Recent studies suggest that a proportion of chronic myeloid leukemia (CML) patients in deep molecular remission can discontinue the tyrosine kinase inhibitor (TKI) treatment without disease relapse. In this multi-center, prospective clinical trial (EURO-SKI, NCT01596114) we analyzed the function and phenotype of T and NK cells and their relation to successful TKI cessation. Lymphocyte subclasses were measured from 100 imatinib treated patients at baseline and 1 month after the discontinuation, and functional characterization of NK and T cells was done from 45 patients. The proportion of NK cells was associated with the molecular relapse free survival as patients with higher than median NK-cell percentage at the time of drug discontinuation had better probability to stay in remission. Similar association was not found with T or B cells or their subsets. In non-relapsing patients the NK-cell phenotype was mature, whereas patients with more naïve CD56(bright) NK cells had decreased relapse free survival. In addition, the TNF-α/IFN-γ cytokine secretion by NK cells correlated with the successful drug discontinuation. Our results highlight the role of NK cells in sustaining remission and strengthen the status of CML as an immunogenic tumor warranting novel clinical trials with immunomodulating agents.
- Published
- 2017
- Full Text
- View/download PDF
8. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
- Author
-
Ilander, M, primary, Olsson-Strömberg, U, additional, Schlums, H, additional, Guilhot, J, additional, Brück, O, additional, Lähteenmäki, H, additional, Kasanen, T, additional, Koskenvesa, P, additional, Söderlund, S, additional, Höglund, M, additional, Markevärn, B, additional, Själander, A, additional, Lotfi, K, additional, Dreimane, A, additional, Lübking, A, additional, Holm, E, additional, Björeman, M, additional, Lehmann, S, additional, Stenke, L, additional, Ohm, L, additional, Gedde-Dahl, T, additional, Majeed, W, additional, Ehrencrona, H, additional, Koskela, S, additional, Saussele, S, additional, Mahon, F-X, additional, Porkka, K, additional, Hjorth-Hansen, H, additional, Bryceson, Y T, additional, Richter, J, additional, and Mustjoki, S, additional
- Published
- 2016
- Full Text
- View/download PDF
9. Immune cell profiling in CML bone marrow by multiplex IHC
- Author
-
Brück, O., primary, Blom, S., additional, Turkki, R., additional, Kovanen, P., additional, Ribeiro, A., additional, Linder, N., additional, Lundin, J., additional, Kallioniemi, O., additional, Pellinen, T., additional, and Mustjoki, S., additional
- Published
- 2016
- Full Text
- View/download PDF
10. 8P - Anti-PD1 therapy increases peripheral blood NKT cells and chemokines in metastatic melanoma patients
- Author
-
Hakanen, H., Hernberg, M., Mäkelä, S., Yadav, B., Brück, O., Juteau, S., Kohtamäki, L., Ilander, M., Mustjoki, S., and Kreutzman, A.
- Published
- 2018
- Full Text
- View/download PDF
11. Zur Bestimmung des Kalks
- Author
-
A. W. B., Hefelmann, R., Stolberg, C., Forte, O., Paguireff, V., Kettler, E., Brück, O., Utz, Hess, W. H., Passon, M., Pellet, H., Haywood, J. K., Stone, W. E., Scheuch, F. C., Knight, N., Maynard, M., Rawson, S. G., Reichard, C., Peters, Ch. A., Walland, H., Rupp, E., Bergdolt, A., Lunge, Krüger, M., Ulke, T., Enright, B., Schultze, E. H., Vizern, Legler, L., d'Anselme, A., and Maigret, E.
- Published
- 1907
- Full Text
- View/download PDF
12. 43P - Immune cell profiling in CML bone marrow by multiplex IHC
- Author
-
Brück, O., Blom, S., Turkki, R., Kovanen, P., Ribeiro, A., Linder, N., Lundin, J., Kallioniemi, O., Pellinen, T., and Mustjoki, S.
- Published
- 2016
- Full Text
- View/download PDF
13. Zur Bestimmung des Kalks
- Author
-
B., A. W., Hefelmann, R., Stolberg, C., Forte, O., Paguireff, V., Kettler, E., Brück, O., Utz, Hess, W. H., Passon, M., Pellet, H., Haywood, J. K., Stone, W. E., Scheuch, F. C., Knight, N., Maynard, M., Rawson, S. G., Reichard, C., Peters, Ch. A., Walland, H., Rupp, E., Bergdolt, A., Lunge, Krüger, M., Ulke, T., Enright, B., Schultze, E. H., Vizern, Legler, L., d'Anselme, A., and Maigret, E.
- Published
- 1907
- Full Text
- View/download PDF
14. Zur gewichtsanalytischen Bestimmung des Calciums
- Author
-
Brück, O.-S.-W.
- Abstract
n/a
- Published
- 1904
15. Zur Constitution der Dibromphtalsäure
- Author
-
Brück, O., primary
- Published
- 1901
- Full Text
- View/download PDF
16. Single-cell characterization of anti-LAG3+anti-PD1 treatment in melanoma patients
- Author
-
Huuhtanen, J, primary, Kasanen, H, additional, Peltola, K, additional, Lönnberg, T, additional, Glumoff, V, additional, Brück, O, additional, Dufva, O, additional, Peltonen, K, additional, Vikkula, J, additional, Jokinen, E, additional, Ilander, M, additional, Lee, MH, additional, Mäkelä, S, additional, Nyakas, M, additional, Li, B, additional, Hernberg, M, additional, Bono, P, additional, Lähdesmäki, H, additional, Kreutman, A, additional, and Mustjoki, S, additional
- Full Text
- View/download PDF
17. European health regulations reduce registry-based research.
- Author
-
Brück O, Sanmark E, Ponkilainen V, Bützow A, Reito A, Kauppila JH, and Kuitunen I
- Subjects
- Humans, Finland, Computer Security, Hospitals, University, Europe, Privacy, European Union, Registries, Biomedical Research, Confidentiality
- Abstract
Background: The European Health Data Space (EHDS) regulation has been proposed to harmonize health data processing. Given its parallels with the Act on Secondary Use of Health and Social Data (Secondary Use Act) implemented in Finland in 2020, this study examines the consequences of heightened privacy constraints on registry-based medical research., Methods: We collected study permit counts approved by university hospitals in Finland in 2014-2023 and the data authority Findata in 2020‒2023. The changes in the study permit counts were analysed before and after the implementation of the General Data Protection Regulation (GDPR) and the Secondary Use Act. By fitting a linear regression model, we estimated the deficit in study counts following the Secondary Use Act., Results: Between 2020 and 2023, a median of 5.5% fewer data permits were approved annually by Finnish university hospitals. On the basis of linear regression modelling, we estimated a reduction of 46.9% in new data permits nationally in 2023 compared with the expected count. Similar changes were neither observed after the implementation of the GDPR nor in permit counts of other medical research types, confirming that the deficit was caused by the Secondary Use Act., Conclusions: This study highlights concerns related to data privacy laws for registry-based medical research and future patient care., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
18. Standardized translations of the Lee Chronic GvHD Symptom Scale to 12 European languages: an EU COST Action cGvHD Eurograft project.
- Author
-
Gjærde LK, Brück O, Gagelmann N, Gavriilaki E, Inngjerdingen M, Keranen M, Kisch A, Myhre AE, Olivieri A, Perez-Simon JA, Perovic D, Perovic V, Piekarska A, Pulanic D, Rathje K, Van Veen S, Dachy G, Moiseev I, Penack O, Peric Z, Greinix H, Lee SJ, Wolff D, and Schoemans H
- Published
- 2024
- Full Text
- View/download PDF
19. The multimodality cell segmentation challenge: toward universal solutions.
- Author
-
Ma J, Xie R, Ayyadhury S, Ge C, Gupta A, Gupta R, Gu S, Zhang Y, Lee G, Kim J, Lou W, Li H, Upschulte E, Dickscheid T, de Almeida JG, Wang Y, Han L, Yang X, Labagnara M, Gligorovski V, Scheder M, Rahi SJ, Kempster C, Pollitt A, Espinosa L, Mignot T, Middeke JM, Eckardt JN, Li W, Li Z, Cai X, Bai B, Greenwald NF, Van Valen D, Weisbart E, Cimini BA, Cheung T, Brück O, Bader GD, and Wang B
- Subjects
- Humans, Microscopy methods, Animals, Single-Cell Analysis methods, Algorithms, Image Processing, Computer-Assisted methods, Deep Learning
- Abstract
Cell segmentation is a critical step for quantitative single-cell analysis in microscopy images. Existing cell segmentation methods are often tailored to specific modalities or require manual interventions to specify hyper-parameters in different experimental settings. Here, we present a multimodality cell segmentation benchmark, comprising more than 1,500 labeled images derived from more than 50 diverse biological experiments. The top participants developed a Transformer-based deep-learning algorithm that not only exceeds existing methods but can also be applied to diverse microscopy images across imaging platforms and tissue types without manual parameter adjustments. This benchmark and the improved algorithm offer promising avenues for more accurate and versatile cell analysis in microscopy imaging., (© 2024. The Author(s), under exclusive licence to Springer Nature America, Inc.)
- Published
- 2024
- Full Text
- View/download PDF
20. Toward an anatomy of human hematopoiesis.
- Author
-
Brück O
- Published
- 2023
- Full Text
- View/download PDF
21. A bibliometric analysis of the gender gap in the authorship of leading medical journals.
- Author
-
Brück O
- Abstract
Background: Monitoring gender representation is critical to achieve diversity and equity in academia. One way to evaluate gender representation in academia is to examine the authorship of research publications. This study sought to determine the gender of first and senior authors of articles in leading medical journals and assess trends in the gender gap over time., Methods: We gather bibliometric data on original research articles (n = 10,558) published in 2010-2019 in five leading medical journals to audit publication and citation frequency by gender. We explored their association with scientific fields, geographical regions, journals, and collaboration scope., Results: We show that there are fewer women as senior (24.8%) than leading authors (34.5%, p < 0.001). The proportion of women varied by country with 9.1% last authors from Austria, 0.9% from Japan, and 0.0% from South Korea. The gender gap decreased longitudinally and faster for the last (-24.0 articles/year, p < 0.001) than first authors (-14.5 articles/year, p = 0.024) with pronounced country-specific variability. We also demonstrate that usage of research keywords varied by gender, partly accounting for the difference in citation counts., Conclusions: In summary, gender representation has increased, although with country-specific variability. The study frame can be easily applied to any journal and time period to monitor changes in gender representation in science., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
22. A bibliometric analysis of geographic disparities in the authorship of leading medical journals.
- Author
-
Brück O
- Abstract
Background: It has previously been reported that authors from developing countries are underrepresented in medical journals. Here, we aimed to build a comprehensive landscape of the geographical representation in medical research publications., Methods: We collected bibliometric data of original research articles (n = 10,558) published between 2010 and 2019 in five leading medical journals and geolocated these by the institute of the corresponding authors. We introduced two simple metrics, the International Research Impact and the Domestic Self-Citation Index, to assess publishing and citing patterns by cities and countries., Results: We show that only 32 countries published more than 10 publications in 10 years equaling 98.9% of all publications. English-speaking countries USA (48.2%), UK (15.9%), Canada (5.3%), and Australia (3.2%) are most represented, but with a declining trend in recent years. When normalized to citation count, 9/32 countries published ≥ 10% more than expected. In total, 85.7% of the publication excess originate from the USA and UK. We demonstrate similar geographical bias at the municipal level. Finally, we discover that journals more commonly publish studies from the country in which the journal is based and authors are more likely to cite work from their own country., Conclusions: The study reveals Anglocentric dominance, domestic preference, but increased geographical representation in recent years in medical publishing. Similar audits could mitigate possible national and regional disparities in any academic field., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
23. Real-world experience of novel multiple myeloma treatments in a large, single-center cohort in Finland.
- Author
-
Loponen H, Mehtälä J, Ylisaukko-Oja T, Brück O, Porkka K, Koskenvesa P, Saukkonen K, and Lievonen J
- Abstract
In this single-center study, we aimed to describe the characteristics, treatment patterns, and outcomes of patients with multiple myeloma (MM) following treatment with bortezomib, carfilzomib, daratumumab, ixazomib, lenalidomide or pomalidomide-based regimens. Data were collected retrospectively from a study cohort of patients receiving a MM treatment in the Hospital District of Helsinki and Uusimaa (HUS) in Finland between 2016-2020. In total, 472 patients were included in the study. Median age was 68.2 years and nearly 25% had a high cytogenetic risk according to the International Myeloma Working Group categorization. In 2018-2020, the spectrum of regimens used as third- or later-line therapy was notably broader than in 2016-2017. The overall response rates for patients who received the most novel regimens (available ≤ 5 years) in second or third line of therapy ( n = 67/430) and fourth line or later ( n = 78/151) were 53.3% and 25.0%, respectively. In this real-world MM patient cohort, the response rates for these novel agents were lower compared to those reported in clinical trials. Given the higher cytogenetic risk profile and more advanced disease stage at the time when treated with novel agents, patients could have benefited from effective novel therapies earlier in their treatment pathway. What is the NEW aspect of your work? (ONE sentence) This study characterized the treatment of Finnish multiple myeloma patients during the era of most novel therapies (after 2016) and also included information on the cytogenetic risk profile of this real-world population.What is the CENTRAL finding of your work? (ONE sentence) There are clear differences between real-world populations treated with most novel combinations and those of randomized controlled trials (RCTs), which is reflected by the poorer treatment outcomes in the real-world setting.What is (or could be) the SPECIFIC clinical relevance of your work? (ONE sentence) Given the high cytogenetic risk profile and advanced disease stage at the time when treated with novel agents, patients could have benefited from effective novel therapies earlier in their treatment pathway., Competing Interests: HL and JM are employees of MedEngine Oy; TY is the owner of MedEngine Oy; KS is an employee and stockholder at Amgen; OB has received consultancy fees from Novartis and Sanofi, outside the submitted work, and consultancy fees from Amgen, in the submitted work; KP and PK declare no conflict of interest; JL has received consultancy fees from Bristol‐Myers Squibb, Sanofi, and Takeda., (© 2023 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
24. Computational textural mapping harmonises sampling variation and reveals multidimensional histopathological fingerprints.
- Author
-
Brummer O, Pölönen P, Mustjoki S, and Brück O
- Subjects
- Humans, Carcinoma, Renal Cell genetics, Carcinoma, Renal Cell pathology, Kidney Neoplasms genetics, Kidney Neoplasms pathology
- Abstract
Background: Technical factors can bias H&E digital slides potentially compromising computational histopathology studies. Here, we hypothesised that sample quality and sampling variation can introduce even greater and undocumented technical fallacy., Methods: Using The Cancer Genome Atlas (TCGA) clear-cell renal cell carcinoma (ccRCC) as a model disease, we annotated ~78,000 image tiles and trained deep learning models to detect histological textures and lymphocyte infiltration at the tumour core and its surrounding margin and correlated these with clinical, immunological, genomic, and transcriptomic profiles., Results: The models reached 95% validation accuracy for classifying textures and 95% for lymphocyte infiltration enabling reliable profiling of ccRCC samples. We validated the lymphocyte-per-texture distributions in the Helsinki dataset (n = 64). Texture analysis indicated constitutive sampling bias by TCGA clinical centres and technically suboptimal samples. We demonstrate how computational texture mapping (CTM) can abrogate these issues by normalising textural variance. CTM-harmonised histopathological architecture resonated with both expected associations and novel molecular fingerprints. For instance, tumour fibrosis associated with histological grade, epithelial-to-mesenchymal transition, low mutation burden and metastasis., Conclusions: This study highlights texture-based standardisation to resolve technical bias in computational histopathology and understand the molecular basis of tissue architecture. All code, data and models are released as a community resource., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
25. Real-world evidence of multiple myeloma treated from 2013 to 2019 in the Hospital District of Helsinki and Uusimaa, Finland.
- Author
-
Vikkula J, Uusi-Rauva K, Ranki T, Toppila I, Aalto-Setälä M, Pousar K, Vassilev L, Porkka K, Silvennoinen R, and Brück O
- Subjects
- Adult, Humans, Finland epidemiology, Stem Cell Transplantation, Hospitals, Retrospective Studies, Multiple Myeloma diagnosis, Multiple Myeloma epidemiology, Multiple Myeloma therapy, Hematopoietic Stem Cell Transplantation adverse effects
- Abstract
Background: The rapid development of multiple myeloma (MM) management underscores the value of real-world data. In our study we examined 509 adult MM patients treated with immunochemotherapy (ICT) with/without stem cell transplantation (SCT) from 2013 to 2019 in the Hospital District of Helsinki and Uusimaa, Finland. Materials & methods: Our study was based on computational analyses of data integrated into the hospital data lake. Results: After 2017, treatment pattern diversity increased with improved access to novel treatments. 5-year survivals were 74.4% (95% CI: 65.5-84.5) in SCT-eligible and 44.0% (95% CI: 37.6-51.4) in non-SCT subgroups. In the SCT-eligible subgroup, high first-year hospitalization costs were followed by stable resource requirements. Conclusion: Hospital data lakes can be adapted to carry out complex analysis of large MM cohorts.
- Published
- 2023
- Full Text
- View/download PDF
26. Single-cell characterization of anti-LAG-3 and anti-PD-1 combination treatment in patients with melanoma.
- Author
-
Huuhtanen J, Kasanen H, Peltola K, Lönnberg T, Glumoff V, Brück O, Dufva O, Peltonen K, Vikkula J, Jokinen E, Ilander M, Lee MH, Mäkelä S, Nyakas M, Li B, Hernberg M, Bono P, Lähdesmäki H, Kreutzman A, and Mustjoki S
- Subjects
- Humans, Programmed Cell Death 1 Receptor, Nivolumab therapeutic use, CD8-Positive T-Lymphocytes, Receptors, Antigen, T-Cell metabolism, Melanoma, Cutaneous Malignant, Melanoma drug therapy, Melanoma genetics, Antineoplastic Agents pharmacology
- Abstract
BackgroundRelatlimab plus nivolumab (anti-lymphocyte-activation gene 3 plus anti-programmed death 1 [anti-LAG-3+anti-PD-1]) has been approved by the FDA as a first-line therapy for stage III/IV melanoma, but its detailed effect on the immune system is unknown.MethodsWe evaluated blood samples from 40 immunotherapy-naive or prior immunotherapy-refractory patients with metastatic melanoma treated with anti-LAG-3+anti-PD-1 in a phase I trial using single-cell RNA and T cell receptor sequencing (scRNA+TCRαβ-Seq) combined with other multiomics profiling.ResultsThe highest LAG3 expression was noted in NK cells, Tregs, and CD8+ T cells, and these cell populations underwent the most significant changes during the treatment. Adaptive NK cells were enriched in responders and underwent profound transcriptomic changes during the therapy, resulting in an active phenotype. LAG3+ Tregs expanded, but based on the transcriptome profile, became metabolically silent during the treatment. Last, higher baseline TCR clonality was observed in responding patients, and their expanding CD8+ T cell clones gained a more cytotoxic and NK-like phenotype.ConclusionAnti-LAG-3+anti-PD-1 therapy has profound effects on NK cells and Tregs in addition to CD8+ T cells.Trial registrationClinicalTrials.gov (NCT01968109)FundingCancer Foundation Finland, Sigrid Juselius Foundation, Signe and Ane Gyllenberg Foundation, Relander Foundation, State funding for university-level health research in Finland, a Helsinki Institute of Life Sciences Fellow grant, Academy of Finland (grant numbers 314442, 311081, 335432, and 335436), and an investigator-initiated research grant from BMS.
- Published
- 2023
- Full Text
- View/download PDF
27. Fibroblast subsets in non-small cell lung cancer: Associations with survival, mutations, and immune features.
- Author
-
Pellinen T, Paavolainen L, Martín-Bernabé A, Papatella Araujo R, Strell C, Mezheyeuski A, Backman M, La Fleur L, Brück O, Sjölund J, Holmberg E, Välimäki K, Brunnström H, Botling J, Moreno-Ruiz P, Kallioniemi O, Micke P, and Östman A
- Subjects
- Humans, Receptor, Platelet-Derived Growth Factor beta analysis, Receptor, Platelet-Derived Growth Factor beta genetics, Receptor, Platelet-Derived Growth Factor beta metabolism, Biomarkers, Tumor metabolism, Fibroblasts metabolism, Fibroblasts pathology, Mutation, Tumor Microenvironment, Carcinoma, Non-Small-Cell Lung pathology, Lung Neoplasms pathology, Cancer-Associated Fibroblasts metabolism
- Abstract
Background: Cancer-associated fibroblasts (CAFs) are molecularly heterogeneous mesenchymal cells that interact with malignant cells and immune cells and confer anti- and protumorigenic functions. Prior in situ profiling studies of human CAFs have largely relied on scoring single markers, thus presenting a limited view of their molecular complexity. Our objective was to study the complex spatial tumor microenvironment of non-small cell lung cancer (NSCLC) with multiple CAF biomarkers, identify novel CAF subsets, and explore their associations with patient outcome., Methods: Multiplex fluorescence immunohistochemistry was employed to spatially profile the CAF landscape in 2 population-based NSCLC cohorts (n = 636) using antibodies against 4 fibroblast markers: platelet-derived growth factor receptor-alpha (PDGFRA) and -beta (PDGFRB), fibroblast activation protein (FAP), and alpha-smooth muscle actin (αSMA). The CAF subsets were analyzed for their correlations with mutations, immune characteristics, and clinical variables as well as overall survival., Results: Two CAF subsets, CAF7 (PDGFRA-/PDGFRB+/FAP+/αSMA+) and CAF13 (PDGFRA+/PDGFRB+/FAP-/αSMA+), showed statistically significant but opposite associations with tumor histology, driver mutations (tumor protein p53 [TP53] and epidermal growth factor receptor [EGFR]), immune features (programmed death-ligand 1 and CD163), and prognosis. In patients with early stage tumors (pathological tumor-node-metastasis IA-IB), CAF7 and CAF13 acted as independent prognostic factors., Conclusions: Multimarker-defined CAF subsets were identified through high-content spatial profiling. The robust associations of CAFs with driver mutations, immune features, and outcome suggest CAFs as essential factors in NSCLC progression and warrant further studies to explore their potential as biomarkers or therapeutic targets. This study also highlights multiplex fluorescence immunohistochemistry-based CAF profiling as a powerful tool for the discovery of clinically relevant CAF subsets., (© The Author(s) 2022. Published by Oxford University Press.)
- Published
- 2023
- Full Text
- View/download PDF
28. An immunity and pyroptosis gene-pair signature predicts overall survival in acute myeloid leukemia.
- Author
-
Kong W, He L, Zhu J, Brück O, Porkka K, Heckman CA, Zhu S, and Aittokallio T
- Subjects
- Cohort Studies, Humans, Prognosis, Retrospective Studies, Leukemia, Myeloid, Acute pathology, Pyroptosis genetics
- Abstract
Treatment responses of patients with acute myeloid leukemia (AML) are known to be heterogeneous, posing challenges for risk scoring and treatment stratification. In this retrospective multi-cohort study, we investigated whether combining pyroptosis- and immune-related genes improves prognostic classification of AML patients. Using a robust gene pairing approach, which effectively eliminates batch effects across heterogeneous patient cohorts and transcriptomic data, we developed an immunity and pyroptosis-related prognostic (IPRP) signature that consists of 15 genes. Using 5 AML cohorts (n = 1327 patients total), we demonstrate that the IPRP score leads to more consistent and accurate survival prediction performance, compared with 10 existing signatures, and that IPRP scoring is widely applicable to various patient cohorts, treatment procedures and transcriptomic technologies. Compared to current standards for AML patient stratification, such as age or ELN2017 risk classification, we demonstrate an added prognostic value of the IPRP risk score for providing improved prediction of AML patients. Our web-tool implementation of the IPRP score and a simple 4-factor nomogram enables practical and robust risk scoring for AML patients. Even though developed for AML patients, our pan-cancer analyses demonstrate a wider application of the IPRP signature for prognostic prediction and analysis of tumor-immune interplay also in multiple solid tumors., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
29. Copy number alterations define outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia.
- Author
-
Hohtari H, Pallisgaard N, Kankainen M, Ellonen P, Brück O, Siitonen T, Säily M, Sinisalo M, Pyörälä M, Itälä-Remes M, Koskenvesa P, Elonen E, Mustjoki S, and Porkka K
- Subjects
- DNA Copy Number Variations, Humans, Philadelphia Chromosome, Precursor Cell Lymphoblastic Leukemia-Lymphoma diagnosis, Precursor Cell Lymphoblastic Leukemia-Lymphoma genetics
- Published
- 2022
- Full Text
- View/download PDF
30. Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation.
- Author
-
Adnan Awad S, Brück O, Shanmuganathan N, Jarvinen T, Lähteenmäki H, Klievink J, Ibrahim H, Kytölä S, Koskenvesa P, Hughes TP, Branford S, Kankainen M, and Mustjoki S
- Subjects
- Epigenesis, Genetic, Genes, Modifier, Humans, Mutation, Protein Kinase Inhibitors, Recurrence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive diagnosis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics, Leukemia, Myeloid genetics
- Published
- 2022
- Full Text
- View/download PDF
31. Clinical Impact of Immune Cells and Their Spatial Interactions in Diffuse Large B-Cell Lymphoma Microenvironment.
- Author
-
Autio M, Leivonen SK, Brück O, Karjalainen-Lindsberg ML, Pellinen T, and Leppä S
- Subjects
- B7-H1 Antigen, Humans, Macrophages metabolism, Prognosis, T-Lymphocytes, Lymphoma, Large B-Cell, Diffuse drug therapy, Tumor Microenvironment genetics
- Abstract
Purpose: Tumor-infiltrating immune cells have prognostic significance and are attractive therapeutic targets. Yet, the clinical significance of their spatial organization and phenotype in diffuse large B-cell lymphoma (DLBCL) is unclear., Experimental Design: We characterized T cells, macrophages, and their spatial interactions by multiplex IHC (mIHC) in 178 patients with DLBCL and correlated the data with patient demographics and survival. We validated the findings on gene expression data from two external DLBCL cohorts comprising 633 patients., Results: Macrophage and T-cell contents divided the samples into T cell-inflamed (60%) and noninflamed (40%) subgroups. The T cell-inflamed lymphoma microenvironment (LME) was also rich in other immune cells, defining immune hot phenotype, which did not as such correlate with outcome. However, when we divided the patients according to T-cell and macrophage contents, LME characterized by high T-cell/low macrophage content or a corresponding gene signature was associated with superior survival [5-year overall survival (OS): 92.3% vs. 74.4%, P = 0.036; 5-year progression-free survival (PFS): 92.6% vs. 69.8%, P = 0.012]. High proportion of PD-L1- and TIM3-expressing CD163- macrophages in the T cell-inflamed LME defined a group of patients with poor outcome [OS: HR = 3.22, 95% confidence interval (CI), 1.63-6.37, Padj = 0.011; PFS: HR = 2.76, 95% CI, 1.44-5.28, Padj = 0.016]. Furthermore, PD-L1 and PD-1 were enriched on macrophages interacting with T cells., Conclusions: Our data demonstrate that the interplay between macrophages and T cells in the DLBCL LME is immune checkpoint dependent and clinically meaningful., (©2021 The Authors; Published by the American Association for Cancer Research.)
- Published
- 2022
- Full Text
- View/download PDF
32. Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia.
- Author
-
Malani D, Kumar A, Brück O, Kontro M, Yadav B, Hellesøy M, Kuusanmäki H, Dufva O, Kankainen M, Eldfors S, Potdar S, Saarela J, Turunen L, Parsons A, Västrik I, Kivinen K, Saarela J, Räty R, Lehto M, Wolf M, Gjertsen BT, Mustjoki S, Aittokallio T, Wennerberg K, Heckman CA, Kallioniemi O, and Porkka K
- Subjects
- Female, Finland, Humans, Leukemia, Myeloid, Acute mortality, Male, Middle Aged, Remission Induction, Survival Analysis, Decision Support Techniques, Leukemia, Myeloid, Acute drug therapy, Patient Care Team, Precision Medicine
- Abstract
We generated ex vivo drug-response and multiomics profiling data for a prospective series of 252 samples from 186 patients with acute myeloid leukemia (AML). A functional precision medicine tumor board (FPMTB) integrated clinical, molecular, and functional data for application in clinical treatment decisions. Actionable drugs were found for 97% of patients with AML, and the recommendations were clinically implemented in 37 relapsed or refractory patients. We report a 59% objective response rate for the individually tailored therapies, including 13 complete responses, as well as bridging five patients with AML to allogeneic hematopoietic stem cell transplantation. Data integration across all cases enabled the identification of drug response biomarkers, such as the association of IL15 overexpression with resistance to FLT3 inhibitors. Integration of molecular profiling and large-scale drug response data across many patients will enable continuous improvement of the FPMTB recommendations, providing a paradigm for individualized implementation of functional precision cancer medicine. SIGNIFICANCE: Oncogenomics data can guide clinical treatment decisions, but often such data are neither actionable nor predictive. Functional ex vivo drug testing contributes significant additional, clinically actionable therapeutic insights for individual patients with AML. Such data can be generated in four days, enabling rapid translation through FPMTB. See related commentary by Letai, p. 290 . This article is highlighted in the In This Issue feature, p. 275 ., (©2021 The Authors; Published by the American Association for Cancer Research.)
- Published
- 2022
- Full Text
- View/download PDF
33. T and NK cell abundance defines two distinct subgroups of renal cell carcinoma.
- Author
-
Lee MH, Järvinen P, Nísen H, Brück O, Ilander M, Uski I, Theodoropoulos J, Kankainen M, Mirtti T, Mustjoki S, and Kreutzman A
- Subjects
- HLA-DR Antigens, Humans, Killer Cells, Natural, Nephrectomy, Carcinoma, Renal Cell genetics, Kidney Neoplasms genetics
- Abstract
Renal cell carcinoma (RCC) is considered as an immunogenic cancer. Because not all patients respond to current immunotherapies, we aimed to investigate the immunological heterogeneity of RCC tumors. We analyzedthe immunophenotype of the circulating, tumor, and matching adjacent healthy kidney immune cells from 52 nephrectomy patients with multi-parameter flow cytometry. Additionally, we studied the transcriptomic and mutation profiles of 20 clear cell RCC (ccRCC) tumors with bulk RNA sequencing and a customized pan-cancer gene panel. The tumor samples clustered into two distinct subgroups defined by the abundance of intratumoral CD3+ T cells (CD3
high , 25/52) and NK cells (NKhigh , 27/52). CD3high tumors had an overall higher frequency of tumor infiltrating lymphocytes and PD-1 expression on the CD8+ T cells compared to NKhigh tumors. The tumor infiltrating T and NK cells had significantly elevated expression levels of LAG-3, PD-1, and HLA-DR compared to the circulating immune cells. Transcriptomic analysis revealed increased immune signaling (IFN-γ, TNF-α via NF-κB, and T cell receptor signaling) and kidney metabolism pathways in the CD3high subgroup. Genomic analysis confirmed the typical ccRCC mutation profile including VHL, PBRM1 , and SETD2 mutations, and revealed PBRM1 as a uniquely mutated gene in the CD3high subgroup. Approximately half of the RCC tumors have a high infiltration of NK cells associated with a lower number of tumor infiltrating lymphocytes, lower PD-1 expression, a distinct transcriptomic and mutation profile, providing insights to the immunological heterogeneity of RCC which may impact treatment responses to immunological therapies., Competing Interests: SM has received honoraria and research funding from Bristol Myers Squibb, Novartis, and Pfizer outside the submitted work. PJ has received funding from Elypta Ab. AK is currently employed by Novartis. OB has received honoraria from Novartis and Sanofi outside the submitted work. The author(s) declare that there are no other conflicts of interest., (© 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.)- Published
- 2022
- Full Text
- View/download PDF
34. Spatial immunoprofiling of the intratumoral and peritumoral tissue of renal cell carcinoma patients.
- Author
-
Brück O, Lee MH, Turkki R, Uski I, Penttilä P, Paavolainen L, Kovanen P, Järvinen P, Bono P, Pellinen T, Mustjoki S, and Kreutzman A
- Subjects
- Adult, Aged, Aged, 80 and over, Biomarkers, Tumor genetics, Carcinoma, Renal Cell genetics, Carcinoma, Renal Cell mortality, Carcinoma, Renal Cell therapy, DNA-Binding Proteins genetics, Female, Humans, Kidney Neoplasms genetics, Kidney Neoplasms mortality, Kidney Neoplasms therapy, Male, Middle Aged, Mutation, Nuclear Proteins genetics, Phenotype, Predictive Value of Tests, Prognosis, Transcription Factors genetics, Tumor Suppressor Proteins genetics, Ubiquitin Thiolesterase genetics, Algorithms, Biomarkers, Tumor analysis, Carcinoma, Renal Cell immunology, Decision Support Techniques, Immunohistochemistry, Immunophenotyping, Kidney Neoplasms immunology, Leukocyte Common Antigens analysis, Lymphocytes, Tumor-Infiltrating immunology, T-Lymphocytes immunology, Tumor Microenvironment immunology
- Abstract
While the abundance and phenotype of tumor-infiltrating lymphocytes are linked with clinical survival, their spatial coordination and its clinical significance remain unclear. Here, we investigated the immune profile of intratumoral and peritumoral tissue of clear cell renal cell carcinoma patients (n = 64). We trained a cell classifier to detect lymphocytes from hematoxylin and eosin stained tissue slides. Using unsupervised classification, patients were further classified into immune cold, hot and excluded topographies reflecting lymphocyte abundance and localization. The immune topography distribution was further validated with The Cancer Genome Atlas digital image dataset. We showed association between PBRM1 mutation and immune cold topography, STAG1 mutation and immune hot topography and BAP1 mutation and immune excluded topography. With quantitative multiplex immunohistochemistry we analyzed the expression of 23 lymphocyte markers in intratumoral and peritumoral tissue regions. To study spatial interactions, we developed an algorithm quantifying the proportion of adjacent immune cell pairs and their immunophenotypes. Immune excluded tumors were associated with superior overall survival (HR 0.19, p = 0.02) and less extensive metastasis. Intratumoral T cells were characterized with pronounced expression of immunological activation and exhaustion markers such as granzyme B, PD1, and LAG3. Immune cell interaction occurred most frequently in the intratumoral region and correlated with CD45RO expression. Moreover, high proportion of peritumoral CD45RO+ T cells predicted poor overall survival. In summary, intratumoral and peritumoral tissue regions represent distinct immunospatial profiles and are associated with clinicopathologic characteristics., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
35. Somatic mutations in lymphocytes in patients with immune-mediated aplastic anemia.
- Author
-
Lundgren S, Keränen MAI, Kankainen M, Huuhtanen J, Walldin G, Kerr CM, Clemente M, Ebeling F, Rajala H, Brück O, Lähdesmäki H, Hannula S, Hannunen T, Ellonen P, Young NS, Ogawa S, Maciejewski JP, Hellström-Lindberg E, and Mustjoki S
- Subjects
- Adult, Aged, Aged, 80 and over, Case-Control Studies, Female, Humans, Male, Middle Aged, Young Adult, Anemia, Aplastic genetics, CD4-Positive T-Lymphocytes metabolism, CD8-Positive T-Lymphocytes metabolism, Mutation genetics
- Abstract
The prevalence and functional impact of somatic mutations in nonleukemic T cells is not well characterized, although clonal T-cell expansions are common. In immune-mediated aplastic anemia (AA), cytotoxic T-cell expansions are shown to participate in disease pathogenesis. We investigated the mutation profiles of T cells in AA by a custom panel of 2533 genes. We sequenced CD4+ and CD8+ T cells of 24 AA patients and compared the results to 20 healthy controls and whole-exome sequencing of 37 patients with AA. Somatic variants were common both in patients and healthy controls but enriched to AA patients' CD8+ T cells, which accumulated most mutations on JAK-STAT and MAPK pathways. Mutation burden was associated with CD8+ T-cell clonality, assessed by T-cell receptor beta sequencing. To understand the effect of mutations, we performed single-cell sequencing of AA patients carrying STAT3 or other mutations in CD8+ T cells. STAT3 mutated clone was cytotoxic, clearly distinguishable from other CD8+ T cells, and attenuated by successful immunosuppressive treatment. Our results suggest that somatic mutations in T cells are common, associate with clonality, and can alter T-cell phenotype, warranting further investigation of their role in the pathogenesis of AA.
- Published
- 2021
- Full Text
- View/download PDF
36. Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma.
- Author
-
Autio M, Leivonen SK, Brück O, Mustjoki S, Mészáros Jørgensen J, Karjalainen-Lindsberg ML, Beiske K, Holte H, Pellinen T, and Leppä S
- Subjects
- Humans, Immunohistochemistry, Lymphocytes, Tumor-Infiltrating, T-Lymphocytes, Cytotoxic, Lymphoma, Large B-Cell, Diffuse genetics, Lymphoma, Large B-Cell, Diffuse therapy, Tumor Microenvironment
- Abstract
The tumor microenvironment (TME) and limited immune surveillance play important roles in lymphoma pathogenesis. Here we aimed to characterize immunological profiles of diffuse large B-cell lymphoma (DLBCL) and predict the outcome in response to immunochemotherapy. We profiled the expression of 730 immune-related genes in tumor tissues of 81 patients with DLBCL utilizing the Nanostring platform, and used multiplex immunohistochemistry to characterize T-cell phenotypes, including cytotoxic T cells (CD8, Granzyme B, OX40, Ki67), T-cell immune checkpoint (CD3, CD4, CD8, PD1, TIM3, LAG3), as well as regulatory T-cells and Th1 effector cells (CD3, CD4, FOXP3, TBET) in 188 patients. We observed a high degree of heterogeneity at the transcriptome level. Correlation matrix analysis identified gene expression signatures with highly correlating genes, the main cluster containing genes for cytolytic factors, immune checkpoint molecules, T cells and macrophages, together named a TME immune cell signature. Immunophenotyping of the distinct cell subsets revealed that a high proportion of immune checkpoint positive T cells translated to unfavorable survival. Together, our results demonstrate that the immunological profile of DLBCL TME is heterogeneous and clinically meaningful. This highlights the potential impact of T-cell immune checkpoint in regulating survival and resistance to immunochemotherapy. (Registered at clinicaltrials.gov identifiers: NCT01502982 and NCT01325194.)
- Published
- 2021
- Full Text
- View/download PDF
37. Immunogenomic Landscape of Hematological Malignancies.
- Author
-
Dufva O, Pölönen P, Brück O, Keränen MAI, Klievink J, Mehtonen J, Huuhtanen J, Kumar A, Malani D, Siitonen S, Kankainen M, Ghimire B, Lahtela J, Mattila P, Vähä-Koskela M, Wennerberg K, Granberg K, Leivonen SK, Meriranta L, Heckman C, Leppä S, Nykter M, Lohi O, Heinäniemi M, and Mustjoki S
- Published
- 2020
- Full Text
- View/download PDF
38. Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients.
- Author
-
Kasanen H, Hernberg M, Mäkelä S, Brück O, Juteau S, Kohtamäki L, Ilander M, Mustjoki S, and Kreutzman A
- Subjects
- Age Factors, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized pharmacology, Antibodies, Monoclonal, Humanized therapeutic use, Antineoplastic Agents, Immunological therapeutic use, Biopsy, CD8-Positive T-Lymphocytes drug effects, CD8-Positive T-Lymphocytes immunology, Drug Resistance, Neoplasm immunology, Female, Follow-Up Studies, Humans, Killer Cells, Natural drug effects, Killer Cells, Natural immunology, Lymphocytes, Tumor-Infiltrating drug effects, Lymphocytes, Tumor-Infiltrating immunology, Male, Melanoma immunology, Melanoma mortality, Melanoma secondary, Middle Aged, Natural Killer T-Cells drug effects, Natural Killer T-Cells immunology, Nivolumab pharmacology, Nivolumab therapeutic use, Programmed Cell Death 1 Receptor immunology, Programmed Cell Death 1 Receptor metabolism, Progression-Free Survival, Skin Neoplasms immunology, Skin Neoplasms mortality, Skin Neoplasms pathology, Aging immunology, Antineoplastic Agents, Immunological pharmacology, Melanoma drug therapy, Programmed Cell Death 1 Receptor antagonists & inhibitors, Skin Neoplasms drug therapy
- Abstract
Anti-PD1 treatment has improved the survival of metastatic melanoma patients, yet it is unknown which patients benefit from the treatment. In this exploratory study, we aimed to understand the effects of anti-PD1 therapy on the patients' immune system and discover the characteristics that would result in successful treatment. We collected peripheral blood (PB) samples from 17 immuno-oncology-naïve metastatic melanoma patients before and after 1 and 3 months of anti-PD1 therapy. In addition, matching tumor biopsies at the time of diagnosis were collected for tissue microarray. The complete blood counts, PB immunophenotype, serum cytokine profiles, and tumor-infiltrating lymphocytes were analyzed and correlated with the clinical data. Patients were categorized based on their disease control into responders (complete response, partial response, stable disease > 6 months, N = 11) and non-responders (progressive disease, stable disease ≤ 6 months, N = 6). During therapy, the PB natural killer T (NKT) cell frequency, expression of CD25 and CD45RO on cytotoxic natural killer (NK) cells, and serum CXC chemokine levels were significantly increased in responders. Furthermore, higher age together with age-associated characteristics from PB, lower frequency of PB-naïve CD8
+ T cells, and elevated levels of serum MCP-4 and OPG were discovered as baseline predictors of treatment response. We therefore propose that in addition to T cells, anti-PD1 treatment is associated with NK- and NKT-cell population dynamics, and that the age-associated characteristics from PB together with older age may contribute to prolonged PFS in anti-PD1-treated melanoma patients.- Published
- 2020
- Full Text
- View/download PDF
39. Prognostic Impact of Tumor-Associated Macrophages on Survival Is Checkpoint Dependent in Classical Hodgkin Lymphoma.
- Author
-
Karihtala K, Leivonen SK, Brück O, Karjalainen-Lindsberg ML, Mustjoki S, Pellinen T, and Leppä S
- Abstract
Tumor microenvironment and immune escape affect pathogenesis and survival in classical Hodgkin lymphoma (cHL). While tumor-associated macrophage (TAM) content has been associated with poor outcomes, macrophage-derived determinants with clinical impact have remained undefined. Here, we have used multiplex immunohistochemistry and digital image analysis to characterize TAM immunophenotypes with regard to expression of checkpoint molecules programmed cell death ligand 1 (PD-L1) and indoleamine 2,3-dioxygenase 1 (IDO-1) from the diagnostic tumor tissue samples of 130 cHL patients, and correlated the findings with clinical characteristics and survival. We show that a large proportion of TAMs express PD-L1 (CD68
+ , median 32%; M2 type CD163+ , median 22%), whereas the proportion of TAMs expressing IDO-1 is lower (CD68+ , median 5.5%; CD163+ , median 1.4%). A high proportion of PD-L1 and IDO-1 expressing TAMs from all TAMs (CD68+ ), or from CD163+ TAMs, is associated with inferior outcome. In multivariate analysis with age and stage, high proportions of PD-L1+ and IDO-1+ TAMs remain independent prognostic factors for freedom from treatment failure (PD-L1+ CD68+ /CD68+ , HR = 2.63, 95% CI 1.17-5.88, p = 0.019; IDO-1+ CD68+ /CD68+ , HR = 2.48, 95% CI 1.03-5.95, p = 0.042). In contrast, proportions of PD-L1+ tumor cells, all TAMs or PD-L1- and IDO-1- TAMs are not associated with outcome. The findings implicate that adverse prognostic impact of TAMs is checkpoint-dependent in cHL.- Published
- 2020
- Full Text
- View/download PDF
40. STAT3 Mutation Is Associated with STAT3 Activation in CD30 + ALK - ALCL.
- Author
-
Andersson EI, Brück O, Braun T, Mannisto S, Saikko L, Lagström S, Ellonen P, Leppä S, Herling M, Kovanen PE, and Mustjoki S
- Abstract
Peripheral T-cell lymphomas (PTCL) are a heterogeneous, and often aggressive group of non-Hodgkin lymphomas. Recent advances in the molecular and genetic characterization of PTCLs have helped to delineate differences and similarities between the various subtypes, and the JAK/STAT pathway has been found to play an important oncogenic role. Here, we aimed to characterize the JAK/STAT pathway in PTCL subtypes and investigate whether the activation of the pathway correlates with the frequency of STAT gene mutations. Patient samples from AITL ( n = 30), ALCL ( n = 21) and PTCL-NOS ( n = 12) cases were sequenced for STAT3 , STAT5B, JAK1, JAK3, and RHOA mutations using amplicon sequencing and stained immunohistochemically for pSTAT3, pMAPK, and pAKT. We discovered STAT3 mutations in 13% of AITL, 13% of ALK
+ ALCL, 38% of ALK- ALCL and 17% of PTCL-NOS cases. However, no STAT5B mutations were found and JAK mutations were only present in ALK- ALCL (15%). Concurrent mutations were found in all subgroups except ALK+ ALCL where STAT3 mutations were always seen alone. High pY-STAT3 expression was observed especially in AITL and ALCL samples. When studying JAK-STAT pathway mutations, pY-STAT3 expression was highest in PTCLs harboring either JAK1 or STAT3 mutations and CD30+ phenotype representing primarily ALK- ALCLs. Further investigation is needed to elucidate the molecular mechanisms of JAK-STAT pathway activation in PTCL.- Published
- 2020
- Full Text
- View/download PDF
41. Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia.
- Author
-
Kuusanmäki H, Leppä AM, Pölönen P, Kontro M, Dufva O, Deb D, Yadav B, Brück O, Kumar A, Everaus H, Gjertsen BT, Heinäniemi M, Porkka K, Mustjoki S, and Heckman CA
- Subjects
- Drug Evaluation, Preclinical, Humans, Phenotype, Sulfonamides, Bridged Bicyclo Compounds, Heterocyclic therapeutic use, Leukemia, Myeloid, Acute diagnosis, Leukemia, Myeloid, Acute drug therapy
- Published
- 2020
- Full Text
- View/download PDF
42. Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival.
- Author
-
Brück O, Dufva O, Hohtari H, Blom S, Turkki R, Ilander M, Kovanen P, Pallaud C, Ramos PM, Lähteenmäki H, Välimäki K, El Missiry M, Ribeiro A, Kallioniemi O, Porkka K, Pellinen T, and Mustjoki S
- Subjects
- Adult, Age Factors, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Survival Analysis, Young Adult, Bone Marrow metabolism, Leukemia, Myeloid, Acute immunology, Receptors, Antigen, T-Cell genetics
- Abstract
The immunologic microenvironment in various solid tumors is aberrant and correlates with clinical survival. Here, we present a comprehensive analysis of the immune environment of acute myeloid leukemia (AML) bone marrow (BM) at diagnosis. We compared the immunologic landscape of formalin-fixed paraffin-embedded BM trephine samples from AML (n = 69), chronic myeloid leukemia (CML; n = 56), and B-cell acute lymphoblastic leukemia (B-ALL) patients (n = 52) at diagnosis to controls (n = 12) with 30 immunophenotype markers using multiplex immunohistochemistry and computerized image analysis. We identified distinct immunologic profiles specific for leukemia subtypes and controls enabling accurate classification of AML (area under the curve [AUC] = 1.0), CML (AUC = 0.99), B-ALL (AUC = 0.96), and control subjects (AUC = 1.0). Interestingly, 2 major immunologic AML clusters differing in age, T-cell receptor clonality, and survival were discovered. A low proportion of regulatory T cells and pSTAT1+cMAF- monocytes were identified as novel biomarkers of superior event-free survival in intensively treated AML patients. Moreover, we demonstrated that AML BM and peripheral blood samples are dissimilar in terms of immune cell phenotypes. To conclude, our study shows that the immunologic landscape considerably varies by leukemia subtype suggesting disease-specific immunoregulation. Furthermore, the association of the AML immune microenvironment with clinical parameters suggests a rationale for including immunologic parameters to improve disease classification or even patient risk stratification., (© 2020 by The American Society of Hematology.)
- Published
- 2020
- Full Text
- View/download PDF
43. Immune cell constitution in bone marrow microenvironment predicts outcome in adult ALL.
- Author
-
Hohtari H, Brück O, Blom S, Turkki R, Sinisalo M, Kovanen PE, Kallioniemi O, Pellinen T, Porkka K, and Mustjoki S
- Subjects
- Adolescent, Adult, Aged, CTLA-4 Antigen, Case-Control Studies, Female, Follow-Up Studies, Humans, Male, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma pathology, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy, Prognosis, Retrospective Studies, Survival Rate, Young Adult, Bone Marrow immunology, CD8-Positive T-Lymphocytes immunology, Hematopoietic Stem Cell Transplantation, Macrophages immunology, Myeloid-Derived Suppressor Cells immunology, Precursor Cell Lymphoblastic Leukemia-Lymphoma immunology, Tumor Microenvironment immunology
- Abstract
As novel immunological treatments are gaining a foothold in the treatment of acute lymphoblastic leukemia (ALL), it is elemental to examine ALL immunobiology in more detail. We used multiplexed immunohistochemistry (mIHC) to study the immune contexture in adult precursor B cell ALL bone marrow (BM). In addition, we developed a multivariate risk prediction model that stratified a poor survival group based on clinical parameters and mIHC data. We analyzed BM biopsy samples of ALL patients (n = 52) and healthy controls (n = 14) using mIHC with 30 different immunophenotype markers and computerized image analysis. In ALL BM, the proportions of M1-like macrophages, granzyme B+CD57+CD8+ T cells, and CD27+ T cells were decreased, whereas the proportions of myeloid-derived suppressor cells and M2-like macrophages were increased. Also, the expression of checkpoint molecules PD1 and CTLA4 was elevated. In the multivariate model, age, platelet count, and the proportion of PD1+TIM3+ double-positive CD4+ T cells differentiated a poor survival group. These results were validated by flow cytometry in a separate cohort (n = 31). In conclusion, the immune cell contexture in ALL BM differs from healthy controls. CD4+PD1+TIM3+ T cells were independent predictors of poor outcome in our multivariate risk model, suggesting that PD1 might serve as an attractive immuno-oncological target in B-ALL.
- Published
- 2019
- Full Text
- View/download PDF
44. Characterization of polydactyly chondrocytes and their use in cartilage engineering.
- Author
-
Cavalli E, Levinson C, Hertl M, Broguiere N, Brück O, Mustjoki S, Gerstenberg A, Weber D, Salzmann G, Steinwachs M, Barreto G, and Zenobi-Wong M
- Subjects
- Adult, Animals, Cattle, Cells, Cultured, Collagen chemistry, Female, Humans, Hyaluronic Acid chemistry, Hydrogels chemistry, Immunohistochemistry, Immunophenotyping, Infant, Kinetics, Male, Mice, Nude, Polymerase Chain Reaction, Transforming Growth Factor beta1 metabolism, Young Adult, Cartilage, Articular cytology, Cartilage, Articular metabolism, Chondrocytes cytology, Chondrocytes metabolism, Tissue Engineering methods
- Abstract
Treating cartilage injuries and degenerations represents an open surgical challenge. The recent advances in cell therapies have raised the need for a potent off-the-shelf cell source. Intra-articular injections of TGF-β transduced polydactyly chondrocytes have been proposed as a chronic osteoarthritis treatment but despite promising results, the use of gene therapy still raises safety concerns. In this study, we characterized infant, polydactyly chondrocytes during in vitro expansion and chondrogenic re-differentiation. Polydactyly chondrocytes have a steady proliferative rate and re-differentiate in 3D pellet culture after up to five passages. Additionally, we demonstrated that polydactyly chondrocytes produce cartilage-like matrix in a hyaluronan-based hydrogel, namely transglutaminase cross-linked hyaluronic acid (HA-TG). We utilized the versatility of TG cross-linking to augment the hydrogels with heparin moieties. The heparin chains allowed us to load the scaffolds with TGF-β1, which induced cartilage-like matrix deposition both in vitro and in vivo in a subcutaneous mouse model. This strategy introduces the possibility to use infant, polydactyly chondrocytes for the clinical treatment of joint diseases.
- Published
- 2019
- Full Text
- View/download PDF
45. T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma.
- Author
-
Leivonen SK, Pollari M, Brück O, Pellinen T, Autio M, Karjalainen-Lindsberg ML, Mannisto S, Kellokumpu-Lehtinen PL, Kallioniemi O, Mustjoki S, and Leppä S
- Subjects
- Adult, Aged, Biomarkers, Biomarkers, Tumor, Computational Biology methods, Female, Gene Expression Profiling, Humans, Immunohistochemistry, Lymphocyte Count, Lymphocytes, Tumor-Infiltrating immunology, Lymphocytes, Tumor-Infiltrating pathology, Male, Middle Aged, Neoplasm Staging, Prognosis, Proportional Hazards Models, T-Lymphocytes immunology, T-Lymphocytes pathology, Testicular Neoplasms mortality, Transcriptome, Lymphocytes, Tumor-Infiltrating metabolism, T-Lymphocytes metabolism, Testicular Neoplasms etiology, Testicular Neoplasms pathology, Tumor Microenvironment genetics, Tumor Microenvironment immunology
- Abstract
Primary testicular lymphoma is a rare lymphoid malignancy, most often, histologically, representing diffuse large B-cell lymphoma. The tumor microenvironment and limited immune surveillance have a major impact on diffuse large B-cell lymphoma pathogenesis and survival, but the impact on primary testicular lymphoma is unknown. Here, the purpose of the study was to characterize the tumor microenvironment in primary testicular lymphoma, and associate the findings with outcome. We profiled the expression of 730 immune response genes in 60 primary testicular lymphomas utilizing the Nanostring platform, and used multiplex immunohistochemistry to characterize the immune cell phenotypes in the tumor tissue. We identified a gene signature enriched for T-lymphocyte markers differentially expressed between the patients. Low expression of the signature predicted poor outcome independently of the International Prognostic Index (progression-free survival: HR=2.810, 95%CI: 1.228-6.431, P =0.014; overall survival: HR=3.267, 95%CI: 1.406-7.590, P =0.006). The T-lymphocyte signature was associated with outcome also in an independent diffuse large B-cell lymphoma cohort (n=96). Multiplex immunohistochemistry revealed that poor survival of primary testicular lymphoma patients correlated with low percentage of CD3
+ CD4+ and CD3+ CD8+ tumor-infiltrating lymphocytes ( P <0.001). Importantly, patients with a high T-cell inflamed tumor microenvironment had a better response to rituximab-based immunochemotherapy, as compared to other patients. Furthermore, loss of membrane-associated human-leukocyte antigen complexes was frequent and correlated with low T-cell infiltration. Our results demonstrate that a T-cell inflamed tumor microenvironment associates with favorable survival in primary testicular lymphoma. This further highlights the importance of immune escape as a mechanism of treatment failure., (Copyright © 2019 Ferrata Storti Foundation.)- Published
- 2019
- Full Text
- View/download PDF
46. PD-L1 + tumor-associated macrophages and PD-1 + tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma.
- Author
-
Pollari M, Brück O, Pellinen T, Vähämurto P, Karjalainen-Lindsberg ML, Mannisto S, Kallioniemi O, Kellokumpu-Lehtinen PL, Mustjoki S, Leivonen SK, and Leppä S
- Subjects
- Aged, Aged, 80 and over, Disease-Free Survival, Humans, Male, Middle Aged, Antigens, Differentiation immunology, B7-H1 Antigen immunology, Lymphocytes, Tumor-Infiltrating immunology, Lymphocytes, Tumor-Infiltrating pathology, Lymphoma, Large B-Cell, Diffuse immunology, Lymphoma, Large B-Cell, Diffuse mortality, Lymphoma, Large B-Cell, Diffuse pathology, Neoplasm Proteins immunology, Programmed Cell Death 1 Receptor immunology, Testicular Neoplasms immunology, Testicular Neoplasms mortality, Testicular Neoplasms pathology
- Abstract
Primary testicular lymphoma is a rare and aggressive lymphoid malignancy, most often representing diffuse large B-cell lymphoma histologically. Tumor-associated macrophages and tumor-infiltrating lymphocytes have been associated with survival in diffuse large B-cell lymphoma, but their prognostic impact in primary testicular lymphoma is unknown. Here, we aimed to identify macrophages, their immunophenotypes and association with lymphocytes, and translate the findings into survival of patients with primary testicular lymphoma. We collected clinical data and tumor tissue from 74 primary testicular lymphoma patients, and used multiplex immunohistochemistry and digital image analysis to examine macrophage markers (CD68, CD163, and c-Maf), T-cell markers (CD3, CD4, and CD8), B-cell marker (CD20), and three checkpoint molecules (PD-L1, PD-L2, and PD-1). We demonstrate that a large proportion of macrophages (median 41%, range 0.08-99%) and lymphoma cells (median 34%, range 0.1-100%) express PD-L1. The quantity of PD-L1
+ CD68+ macrophages correlates positively with the amount of PD-1+ lymphocytes, and a high proportion of either PD-L1+ CD68+ macrophages or PD-1+ CD4+ and PD-1+ CD8+ T cells translates into favorable survival. In contrast, the number of PD-L1+ lymphoma cells or PD-L1- macrophages do not associate with outcome. In multivariate analyses with IPI, PD-L1+ CD68+ macrophage and PD-1+ lymphocyte contents remain as independent prognostic factors for survival. In conclusion, high PD-L1+ CD68+ macrophage and PD-1+ lymphocyte contents predict favorable survival in patients with primary testicular lymphoma. The findings implicate that the tumor microenvironment and PD-1 - PD-L1 pathway have a significant role in regulating treatment outcome. They also bring new insights to the targeted thera py of primary testicular lymphoma., (Copyright© 2018 Ferrata Storti Foundation.)- Published
- 2018
- Full Text
- View/download PDF
47. Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML.
- Author
-
Brück O, Blom S, Dufva O, Turkki R, Chheda H, Ribeiro A, Kovanen P, Aittokallio T, Koskenvesa P, Kallioniemi O, Porkka K, Pellinen T, and Mustjoki S
- Subjects
- Adult, Aged, Aged, 80 and over, Biomarkers, Biopsy, Female, Flow Cytometry, Histocompatibility Antigens Class I immunology, Humans, Immunohistochemistry, Immunomodulation, Leukemia, Myelogenous, Chronic, BCR-ABL Positive therapy, Leukocyte Count, Lymphocyte Count, Male, Middle Aged, Myeloid-Derived Suppressor Cells immunology, Myeloid-Derived Suppressor Cells metabolism, Protein Kinase Inhibitors administration & dosage, Protein Kinase Inhibitors adverse effects, Protein Kinase Inhibitors therapeutic use, T-Lymphocyte Subsets immunology, T-Lymphocyte Subsets metabolism, T-Lymphocytes metabolism, T-Lymphocytes pathology, Tissue Array Analysis, Treatment Outcome, Young Adult, Bone Marrow immunology, Bone Marrow pathology, Leukemia, Myelogenous, Chronic, BCR-ABL Positive immunology, Leukemia, Myelogenous, Chronic, BCR-ABL Positive pathology, T-Lymphocytes immunology, Tumor Microenvironment immunology
- Abstract
Increasing evidence suggests that the immune system affects prognosis of chronic myeloid leukemia (CML), but the detailed immunological composition of the leukemia bone marrow (BM) microenvironment is unknown. We aimed to characterize the immune landscape of the CML BM and predict the current treatment goal of tyrosine kinase inhibitor (TKI) therapy, molecular remission 4.0 (MR4.0). Using multiplex immunohistochemistry (mIHC) and automated image analysis, we studied BM tissues of CML patients (n = 56) and controls (n = 14) with a total of 30 immunophenotype markers essential in cancer immunology. CML patients' CD4+ and CD8+ T-cells expressed higher levels of putative exhaustion markers PD1, TIM3, and CTLA4 when compared to control. PD1 expression was higher in BM compared to paired peripheral blood (PB) samples, and decreased during TKI therapy. By combining clinical parameters and immune profiles, low CD4+ T-cell proportion, high proportion of PD1+TIM3-CD8+ T cells, and high PB neutrophil count were most predictive of lower MR4.0 likelihood. Low CD4+ T-cell proportion and high PB neutrophil counts predicted MR4.0 also in a validation cohort (n = 52) analyzed with flow cytometry. In summary, the CML BM is characterized by immune suppression and immune biomarkers predicted MR4.0, thus warranting further testing of immunomodulatory drugs in CML treatment.
- Published
- 2018
- Full Text
- View/download PDF
48. Somatic STAT3 mutations in Felty syndrome: an implication for a common pathogenesis with large granular lymphocyte leukemia.
- Author
-
Savola P, Brück O, Olson T, Kelkka T, Kauppi MJ, Kovanen PE, Kytölä S, Sokka-Isler T, Loughran TP, Leirisalo-Repo M, and Mustjoki S
- Subjects
- Adult, Aged, Cytokines analysis, DNA Mutational Analysis, Diagnosis, Differential, Felty Syndrome classification, Felty Syndrome diagnosis, Felty Syndrome pathology, Female, High-Throughput Nucleotide Sequencing, Humans, Leukemia, Large Granular Lymphocytic classification, Leukemia, Large Granular Lymphocytic diagnosis, Leukemia, Large Granular Lymphocytic pathology, Male, Middle Aged, Mutation, Phenotype, Phosphorylation, STAT3 Transcription Factor metabolism, STAT5 Transcription Factor, src Homology Domains genetics, Felty Syndrome genetics, Leukemia, Large Granular Lymphocytic genetics, STAT3 Transcription Factor genetics
- Abstract
Felty syndrome is a rare disease defined by neutropenia, splenomegaly, and rheumatoid arthritis. Sometimes the differential diagnosis between Felty syndrome and large granular lymphocyte leukemia is problematic. Recently, somatic STAT3 and STAT5B mutations were discovered in 30-40% of patients with large granular lymphocyte leukemia. Herein, we aimed to study whether these mutations can also be detected in Felty syndrome, which would imply the existence of a common pathogenic mechanism between these two disease entities. We collected samples and clinical information from 14 Felty syndrome patients who were monitored at the rheumatology outpatient clinic for Felty syndrome. Somatic STAT3 mutations were discovered in 43% (6/14) of Felty syndrome patients with deep amplicon sequencing targeting all STAT3 exons. Mutations were located in the SH2 domain of STAT3 , which is a known mutational hotspot. No STAT5B mutations were found. In blood smears, overrepresentation of large granular lymphocytes was observed, and in the majority of cases the CD8
+ T-cell receptor repertoire was skewed when analyzed by flow cytometry. In bone marrow biopsies, an increased amount of phospho-STAT3 positive cells was discovered. Plasma cytokine profiling showed that ten of the 92 assayed cytokines were elevated both in Felty syndrome and large granular lymphocyte leukemia, and three of these cytokines were also increased in patients with uncomplicated rheumatoid arthritis. In conclusion, somatic STAT3 mutations and STAT3 activation are as frequent in Felty syndrome as they are in large granular lymphocyte leukemia. Considering that the symptoms and treatment modalities are also similar, a unified reclassification of these two syndromes is warranted., (Copyright© 2018 Ferrata Storti Foundation.)- Published
- 2018
- Full Text
- View/download PDF
49. Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner.
- Author
-
Kreutzman A, Colom-Fernández B, Jiménez AM, Ilander M, Cuesta-Mateos C, Pérez-García Y, Arévalo CD, Brück O, Hakanen H, Saarela J, Ortega-Carrión A, de Rosendo A, Juanes-García A, Steegmann JL, Mustjoki S, Vicente-Manzanares M, and Muñoz-Calleja C
- Subjects
- Actins metabolism, Animals, Cell Line, Tumor, Dasatinib adverse effects, Endothelial Cells drug effects, Endothelial Cells pathology, Gene Expression Regulation, Neoplastic drug effects, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive metabolism, Leukemia, Myelogenous, Chronic, BCR-ABL Positive pathology, Mice, Myosin Heavy Chains, Wound Healing drug effects, Xenograft Model Antitumor Assays, rho-Associated Kinases metabolism, Dasatinib administration & dosage, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Molecular Motor Proteins agonists, rho-Associated Kinases genetics
- Abstract
Purpose: Dasatinib is a short-acting dual ABL/SRC family tyrosine kinase inhibitor (TKI), which is frequently used to treat chronic myeloid leukemia. Although very effective, patients taking dasatinib often display severe adverse effects, including pleural effusions and increased risk of bleeding primarily in the gastrointestinal tract. The actual causes of these side effects are currently undetermined. We hypothesize that endothelial cells (ECs) that line the inner walls of blood vessels and control the traffic to the underlying tissues might be involved. Experimental Design: The effects of TKIs on ECs were studied by various assays, such as real-time cell impedance measurements, live-cell microscopy, wound healing, Western blot, and an in vivo model. Results: Dasatinib uniquely causes a profound, dose-dependent disorganization of the EC monolayers. Dasatinib promoted the disassembly of cell-cell contacts, altered cell-matrix contacts, and further altered the wound healing. A key observation is that this effect is fully reversible after drug washout. In line with these in vitro observations, intraperitoneal administration of dasatinib to mice caused significant vascular leakage in the intestine. The underlying molecular mechanism of dasatinib-induced reorganization of the actin involves ROCK activation, which increases the amount of the phosphorylation of myosin light chain and consequently activates the non-muscle myosin II. Conclusions: Our data are consistent with a scenario in which dasatinib triggers a transient increase in vascular leakage that probably contributes to adverse effects such as bleeding diathesis and pleural effusions. Clin Cancer Res; 23(21); 6697-707. ©2017 AACR ., (©2017 American Association for Cancer Research.)
- Published
- 2017
- Full Text
- View/download PDF
50. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.
- Author
-
Ilander M, Olsson-Strömberg U, Schlums H, Guilhot J, Brück O, Lähteenmäki H, Kasanen T, Koskenvesa P, Söderlund S, Höglund M, Markevärn B, Själander A, Lotfi K, Dreimane A, Lübking A, Holm E, Björeman M, Lehmann S, Stenke L, Ohm L, Gedde-Dahl T, Majeed W, Ehrencrona H, Koskela S, Saussele S, Mahon FX, Porkka K, Hjorth-Hansen H, Bryceson YT, Richter J, and Mustjoki S
- Subjects
- Case-Control Studies, Cytokines metabolism, Dasatinib therapeutic use, Disease-Free Survival, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive pathology, Lymphocyte Count, Lymphocyte Subsets cytology, Protein Kinase Inhibitors therapeutic use, Pyrimidines therapeutic use, Withholding Treatment, Imatinib Mesylate therapeutic use, Killer Cells, Natural cytology, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy
- Abstract
Recent studies suggest that a proportion of chronic myeloid leukemia (CML) patients in deep molecular remission can discontinue the tyrosine kinase inhibitor (TKI) treatment without disease relapse. In this multi-center, prospective clinical trial (EURO-SKI, NCT01596114) we analyzed the function and phenotype of T and NK cells and their relation to successful TKI cessation. Lymphocyte subclasses were measured from 100 imatinib-treated patients at baseline and 1 month after the discontinuation, and functional characterization of NK and T cells was done from 45 patients. The proportion of NK cells was associated with the molecular relapse-free survival as patients with higher than median NK-cell percentage at the time of drug discontinuation had better probability to stay in remission. Similar association was not found with T or B cells or their subsets. In non-relapsing patients the NK-cell phenotype was mature, whereas patients with more naïve CD56
bright NK cells had decreased relapse-free survival. In addition, the TNF-α/IFN-γ cytokine secretion by NK cells correlated with the successful drug discontinuation. Our results highlight the role of NK cells in sustaining remission and strengthen the status of CML as an immunogenic tumor warranting novel clinical trials with immunomodulating agents.- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.